Cardiac Amyloidosis for the Primary Care Provider: A Practical Review to Promote Earlier Recognition of Disease.

Autor:	Zhang KW; Cardio-Oncology Center of Excellence, Washington University School of Medicine, St Louis Mo. Electronic address: kwzhang@wustl.edu., Vallabhaneni S; Cardio-Oncology Center of Excellence, Washington University School of Medicine, St Louis Mo., Alvarez-Cardona JA; Cardio-Oncology Center of Excellence, Washington University School of Medicine, St Louis Mo., Krone RJ; Cardio-Oncology Center of Excellence, Washington University School of Medicine, St Louis Mo., Mitchell JD; Cardio-Oncology Center of Excellence, Washington University School of Medicine, St Louis Mo., Lenihan DJ; Cardio-Oncology Center of Excellence, Washington University School of Medicine, St Louis Mo.
Jazyk:	angličtina
Zdroj:	The American journal of medicine [Am J Med] 2021 May; Vol. 134 (5), pp. 587-595. Date of Electronic Publication: 2021 Jan 12.
DOI:	10.1016/j.amjmed.2020.11.031
Abstrakt:	Cardiac amyloidosis is increasingly recognized as an underdiagnosed cause of heart failure. Diagnostic delays of up to 3 years from symptom onset may occur, and patients may be evaluated by more than 5 specialists prior to receiving the correct diagnosis. Newly available therapies improve clinical outcomes by preventing amyloid fibril deposition and are usually more effective in early stages of disease, making early diagnosis essential. Better awareness among primary care providers of the clinical presentation and modern treatment landscape is essential to improve timely diagnosis and early treatment of this disease. In this review, we provide practical guidance on the epidemiology, clinical manifestations, diagnostic evaluation, and treatment of transthyretin and light chain cardiac amyloidosis to promote earlier disease recognition among primary care providers. (Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu